Tesnatilimab  (Synonyms: JNJ-64304500; IPH-2301; NN-8555)

Tesnatilimab (JNJ-64304500) is a human IgG4 monoclonal antibody targeting NKG2D, with a K_D value of 9.2 pM^[1][2]. Tesnatilimab blocks the binding of ligands to the NKG2D receptor, thereby inhibiting downstream proinflammatory cytokine, cytotoxic mediator signaling pathways and proinflammatory immune responses. Tesnatilimab is applicable to research related to Crohn's disease^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

NKG2D/CD314

Tesnatilimab (2 weeks) maintains nearly complete NKG2D receptor occupancy (≥ 95%) on CD8+ T cells and NK cells in peripheral blood^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

22914  [NCBI] & 100528032  [NCBI]

P26718

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.9 kDa

2242758-08-1

Liquid

Colorless to light yellow

[Tesnatilimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Flow Cytometry analysis of Ramos cells labelling CD314 (red) with Tesnatilimab (HY-P99389). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 kappa (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Immobilized NKG2D/CD314 Protein, Human can bind Tesnatilimab. The EC₅₀ for this effect is 16.41 ng/mL.

• [1]. Zhou J, et al. Model-Based Investigation of Inadequate Efficacy of Tesnatilimab, an Anti-Natural Killer Group 2 Member D Monoclonal Antibody, in Moderately to Severely Active Crohn Disease. J Clin Pharmacol. 2023;63(8):928-942.

  [2]. Allez M, et al. A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's Disease. J Crohns Colitis. 2023;17(8):1235-1251.